MET and prostate carcinoma: In summary, this study identifies SEMA3C as a key secreted, autocrine growth factor that drives PCa growth and castration‐ and treatment‐resistant prostate cancer progression through activation of EGFR, HER2/ErbB2, MET, and c‐SRC tyrosine kinase pathways.